These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21761341)

  • 1. Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Wang L; Chan MS; Wing L; Yiu CC; Chow LW; Sasano H
    Horm Cancer; 2011 Feb; 2(1):73-81. PubMed ID: 21761341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
    Suzuki T; Miki Y; Moriya T; Akahira J; Ishida T; Hirakawa H; Yamaguchi Y; Hayashi S; Sasano H
    Int J Cancer; 2007 Jan; 120(2):285-91. PubMed ID: 17066438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.
    Yoda T; McNamara KM; Miki Y; Takagi M; Rai Y; Ohi Y; Sagara Y; Tamaki K; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H
    Cancer Sci; 2014 Nov; 105(11):1503-9. PubMed ID: 25230018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
    Takagi K; Miki Y; Nagasaki S; Hirakawa H; Onodera Y; Akahira J; Ishida T; Watanabe M; Kimijima I; Hayashi S; Sasano H; Suzuki T
    Endocr Relat Cancer; 2010 Jun; 17(2):415-30. PubMed ID: 20228125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
    Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
    Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.
    McNamara KM; Yoda T; Miki Y; Chanplakorn N; Wongwaisayawan S; Incharoen P; Kongdan Y; Wang L; Takagi K; Mayu T; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Ohuchi N; Sasano H
    Cancer Sci; 2013 May; 104(5):639-46. PubMed ID: 23373898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
    Chow LW; Wong JL; Toi M
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):443-7. PubMed ID: 14623542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
    Suzuki T; Darnel AD; Akahira JI; Ariga N; Ogawa S; Kaneko C; Takeyama J; Moriya T; Sasano H
    J Clin Endocrinol Metab; 2001 May; 86(5):2250-7. PubMed ID: 11344235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
    Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
    Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer.
    Shibahara Y; Miki Y; Sakurada C; Uchida K; Hata S; McNamara K; Yoda T; Takagi K; Nakamura Y; Suzuki T; Ishida T; Ohuchi N; Sasano H
    Hum Pathol; 2013 Oct; 44(10):2338-45. PubMed ID: 23953348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New development in intracrinology of breast carcinoma.
    Sasano H; Suzuki T; Nakata T; Moriya T
    Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Yiu CC; Chanplakorn N; Chan MS; Loo WT; Chow LW; Toi M; Sasano H
    Anticancer Res; 2010 Sep; 30(9):3465-72. PubMed ID: 20944124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
    Negri-Cesi P; Colciago A; Poletti A; Motta M
    Prostate; 1999 Dec; 41(4):224-32. PubMed ID: 10544295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.